Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676850 | 1.00 | HMGCR (0.46) | HMGCRPTPN1PTPN11PTPN2ALOX15 | |
| SCHEMBL5678820 | 0.97 | HMGCR (0.49) | HMGCRPTPN1PTPN11PTPN2PRKCI | |
| SCHEMBL5676155 | 0.91 | ALOX15 (0.42) | HMGCRALOX15ALOX12 | |
| SCHEMBL5676361 | 0.90 | HMGCR (0.44) | HMGCRPTPN1PTPN11PTPN2PPARG | |
| SCHEMBL5193693 | 0.90 | TYR (0.40) | HMGCRPTPN1PPARGPPARAPTGES | |
| SCHEMBL5680663 | 0.90 | TYR (0.40) | HMGCRPTPN1PPARGPPARAPTGES | |
| SCHEMBL5675982 | 0.89 | PTGES (0.44) | HMGCRPTPN1ALOX15MAPTPPARG | |
| SCHEMBL5680890 | 0.89 | PTGES (0.44) | HMGCRPTPN1ALOX15MAPTPPARG | |
| SCHEMBL5677851 | 0.89 | PTGES (0.44) | PTPN1ALOX15MAPTPPARGPPARA | |
| SCHEMBL5678294 | 0.89 | PTGES (0.44) | PTPN1ALOX15MAPTPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | HMGCR 3490/4885PTPN1 4673/4885PTPN11 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.